Evidence map›Paper›PMID 24997401›Full record

ArticleCurrent opinion in microbiology2014

Bacteriophage-based synthetic biology for the study of infectious diseases.

Robert J Citorik, Mark Mimee, Timothy K Lu

Open access · hybridAbstract read
In one paragraph

Article in Current opinion in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
9.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Bacteriophage Technology and Modern Medicine.Antibiotics (Basel, Switzerland) · 2021
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robert J Citorik *MIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
Mark Mimee *MIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
Timothy K LuMIT Microbiology Program, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
IIT@MIT · US

Funding

Interdepartmental Biotechnology Training ProgramT32GM008334 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WITTRUP, KARL DANE · 1989 to 2018
$15.2M
MIT Center for Integrative Synthetic BiologyP50GM098792 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WEISS, RON · 2013 to 2017
$11.0M
High-Throughput Nanoscale Approaches to Studying and Inhibiting Amyloid ToxicityDP2OD008435 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LU, TIMOTHY · 2011 to 2011
$2.4M
Howard Hughes Medical InstituteNIGMS NIH HHS 5T32 GM008334NIGMS NIH HHS P50 GM098792NIGMS NIH HHS T32 GM008334NIH HHS DP2 OD008435
6 · The paper itself

Abstract

Since their discovery, bacteriophages have contributed enormously to our understanding of molecular biology as model systems. Furthermore, bacteriophages have provided many tools that have advanced the fields of genetic engineering and synthetic biology. Here, we discuss bacteriophage-based technologies and their application to the study of infectious diseases. New strategies for engineering genomes have the potential to accelerate the design of novel phages as therapies, diagnostics, and tools. Though almost a century has elapsed since their discovery, bacteriophages continue to have a major impact on modern biological sciences, especially with the growth of multidrug-resistant bacteria and interest in the microbiome.

Indexed as

BacteriophagesCommunicable DiseasesSynthetic BiologyResearch

Identifiers

PMID24997401
PMCPMC4125527
OpenAlexW1988416860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.